menu search

ischemia reperfusion injury therapeutics market revenue to cross usd 3.2 billion by 2031 at a cagr of 3.5%: transparency market research inc.

Increasing prevalence of cardiovascular diseases, increase in geriatric population and surge in awareness about ...

September 4, 2023, 10:10 am

Critical limb ischemia treatment market to grow at an 8.03% cagr from 2023 to 2031, reaching usd 3.49 billion: tmr report

Increasing popularity of effective medications like beta-blockers, antiplatelet drugs, and statins is expected to drive critical limb ...

July 24, 2023, 4:00 pm

More angina relief with complete revascularization in stable cad: ischemia

Complete revascularization with PCI results in better health status for patients with multivessel, stable CAD than either incomplete revascularization...

July 18, 2023, 8:59 pm

Revive therapeutics receives orphan drug designation for bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for ...

February 16, 2022, 7:30 am

Revive therapeutics receives orphan drug designation for bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for ...

February 16, 2022, 7:30 am

Revive therapeutics receives orphan drug designation for bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for ...

February 16, 2022, 7:30 am


Search within

Pages Search Results: